Ocular Insert Retention Structure for Conjunctival Sac
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ocular insert devices for drug delivery to the eye face challenges such as limited retention time, discomfort, propensity for displacement, interference with vision, and difficulty with placement and removal, leading to less than ideal drug delivery and patient compliance.
Innovation Solution
The development of improved ocular inserts with a resistance to deflection, designed to be comfortably placed on the conjunctiva, providing enhanced retention and compliance. These inserts can be configured with a matrix containing a therapeutic agent and resistance to deflection, allowing them to move with the eye while remaining in place for an extended time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ocular inserts are placed on the conjunctiva for extended retention, then drug delivery efficacy is improved, but patient comfort deteriorates due to displacement and interference with vision
Solution Approach 1:
The ocular insert is divided into multiple segments or zones with different properties. The retention portion has high adhesion to maintain placement, while the optical zone maintains transparency to avoid vision interference. This segmentation allows different regions to fulfill conflicting requirements simultaneously.
Solution Approach 2:
Different regions of the ocular insert have locally optimized properties. The conjunctival contact area has high adhesion for retention, the optical zone has high transparency for vision, and the drug release area has controlled porosity. This local quality differentiation resolves the contradiction between retention and comfort.
2Duration of action of moving object
If ocular inserts are designed for sustained release, then treatment efficacy is improved, but device complexity increases making placement and removal difficult
Solution Approach 1:
The complex sustained-release mechanism is extracted from a separate device and integrated directly into the ocular insert structure itself. The drug matrix and release mechanism are combined with the retention structure, simplifying the overall device while maintaining sustained release functionality.
Solution Approach 2:
Multiple functions are merged into a single integrated structure: the ocular insert combines retention functionality, drug storage, and sustained release mechanism in one piece. This merging reduces device complexity compared to multi-component systems while achieving prolonged drug delivery.
3Reliability
If ocular inserts use adhesive materials for retention, then placement stability is improved, but comfort deteriorates due to irritation and hyperemia
Solution Approach 1:
An intermediary lubricous coating is applied between the ocular insert and the conjunctiva. This coating layer reduces direct contact irritation while maintaining adequate retention, acting as a mediator that allows the insert to stay in place without causing harmful effects.
Solution Approach 2:
The adhesive properties of the ocular insert are carefully controlled within an optimal range. The material is designed to have sufficient adhesion for retention but not excessive adhesion that would cause irritation. Parameters such as adhesion strength, elasticity, and surface properties are optimized to balance retention and comfort.
Data Source
AI summary
A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.